SynthesisPediatric research2026
Impact on mortality of inhaled nitric oxide in newborns ≤34 weeks with early hypoxemic respiratory failure: systematic review and meta-analysis.
Synthesis in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInhaled nitric oxide (iNO) is approved for hypoxemic respiratory failure (HRF) associated with pulmonary hypertension (PH) in term and near-term neonates; however, its use in preterm infants ≤34 weeks' gestation remains controversial, with limited and inconsistent evidence of survival benefit.
objectiveTo evaluate the association between iNO use and mortality in preterm neonates ≤34 weeks' gestation.
methodsA systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. Major databases were searched up to October 11, 2025. Observational studies and clinical trials reporting mortality in preterm infants with early HRF treated with iNO were included. A random-effects meta-analysis was performed.
resultsNineteen studies were included in the qualitative synthesis, and six (n = 556 infants) in the meta-analysis. Study quality ranged from poor to good, with limitations related to confounding and heterogeneity. No significant reduction in mortality was observed with iNO compared with standard care (RR 0.65; 95% CI 0.29-1.48; I² = 55.7%). Infants receiving iNO were more severely ill at baseline. A positive oxygenation response was associated with improved outcomes and varied by gestational age (GA), timing of PH onset, echocardiographic confirmation, and hypoxemia severity.
conclusionsCurrent evidence regarding the survival benefit of iNO in preterm infants ≤34 weeks remains inconclusive. IMPACT: This systematic review and meta-analysis show that inhaled nitric oxide (iNO) is not associated with a consistent reduction in mortality in preterm infants ≤34 weeks at the population level. It adds evidence that outcomes are strongly influenced by clinical context, particularly, illness severity, gestational age, timing of pulmonary hypertension onset, echocardiographic confirmation, and response to therapy. These findings support a selective, phenotype-driven approach rather than routine iNO use in all preterm infants with hypoxemic respiratory failure. The results may inform clinical decision-making and highlight the need for well-designed randomized trials in this high-risk population.
Identifiers
42864401What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.